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RESUMEN 
Dos nuevos beta agonistas de efecto prolongado son actualmente usados clínicamente: 
salmeterol y formoterol. El primero no ha demostrado efectividad en los casos de asma 
aguda mientras que el segundo, Formoterol, comparable en su período de latencia al 
albuterol, no ha sido empleado en el manejo de las crisis de asma. En este estudio 
utilizamos mediciones de flujo espiratorio pico antes y después de la administración de 
12 microgramos de Fumarato de Formoterol (Foradil®) en polvo seco vía nebulización, 
inmediatamente después de su diluición en solución salina estéril, a treinta pacientes 
con crisis de asma y grados variables de obstrucción bronquial. Los resultados muestran 
mejoría significativa a los 5 y 30 minutos después de su administración, sugiriendo 
estabilidad de este producto así como un novedoso enfoque costo efectivo por su menor 
dosificación y posible impacto sobre la frecuencia de readmisiones debido a una 
broncodilatación prolongada. 
Palabras Clave: Formoterol, Solución nebulizadora, Manejo de ataque agudo de asma, 
Agonista Beta 2 de acción larga. 
ABSTRACT 
Salmeterol and Formoterol, two new long acting Beta agonists, are being clinically 
employed. Salmeterol lacks efficacy in acute asthma while Formoterol, with a latency 
period similar to albuterol, has never been used in the acute bronchospastic situation. 
We measured peak expiratory flows in 30 acute asthma patients with variable degrees of 
airway obstruction before and after administation of 12 micrograms of Formoterol 
Fumarate (Foradil®) dry powder, nebulized inmediatly after preparation in sterile saline 
solution. We found significant improvements at 5 and 30 minutes after administration 
suggesting stability of this product and a possible new cost effective approach with a 
need for less dosing and perhaps an impact on the rate of asthma readmisions due to the 
prolonged bronchodilatador effect. 
Key Words: Formoterol, Nebulized solution, Asthma acute management, Long acting 
Beta 2 agonist. 
INTRODUCTION 
Frequent use of inhaled (either via MDI or by nebulization) short acting beta agonists is 
the routine pharmacological treatment for acute asthma exacerbations. Long acting beta 
agonists have been used in primary care as valuable adjuncts to maintenance inhaled 
steroids and for symptom control with emphasis on nocturnal and exercise induced 
asthma(1). Formoterol fumarate* (* (+ -) -2´- hydroxi-5´-[(RS)-1-hydroxi-2-[(RS)-p-
methoxy-alfa-methylphenethyl]-amino]ethyl]-formanilidin dihydrated fumarate), a new 
long acting (dry powder) beta agonist, also has an acute rapid bronchodilating effect 
comparable to albuterol, suggesting its potential use as an occasional symptom reliever 
on a pro re nata basis(2). There are patients unable to properly perform inhalatory 
efforts because of age, breathing difficulties or other factors and in such instances 
administration of a drug via a nebulized solution can prove helpful. We employed 
formoterol as a dry powder in saline solution nebulized inmediatly after preparation to 
patients with acute asthma, in an open uncontrolled study. 
METHODOLOGY 
Consecutive patients with asthma, as defined by the American Thoracic Society(3), 
attending the emergency room with acute wheezing exacerbations and able to perform a 
peak expiratory maneuver were evaluated clinically and with Peak Expiratory Flow 
(PEF) measurements (Personal Best®, the best of three measurements in the standing 
position) before, 5 minutes and 30 minutes after nebulization with a single dose of 12 
micrograms of Formoterol (Foradil®: 1 capsule diluted in 2 ml of sterile saline 
solution). The pH of the nebulization solution did not differ from sterile normal 
saline(4) and was administered inmediately after preparation with a Pari® Jet nebulizer 
connected to a De Vilbiss® compressor model 5650 D with an output of 0.15 - 0.35 
ml/min. Patients with clinical evidence of possible bacterial infection such as high 
fever, purulent bronchitis and or pneumonitis, as well as those who had received any 
beta agonists in the previous 4 hours, were excluded. In those patients unable to use the 
nebulizer mouth piece, a face mask was used as a substitute. The protocol and informed 
consent document were approved by the Institutional Review Ethical board (Instituto de 
Clínicas y Urología Tamanaco) and written informed consent was obtained from all 
patients or parents prior to participation. The student "t" test was employed for the 
statistical analysis. 
RESULTS 
Thirty (30) patients (male 11, ages 4 to 62, mean of 25. 6 years), with variable degrees 
of airway obstruction were studied. A reduction in the mean PEF value of 47.8% of 
predicted was found before treatment, progressing to 27.9% and 19.9% at 5 minutes and 
30 minutes respectively. Mean values for PEF are shown in Table 1. 
Table 1. 
PEF predicted PEF 0 min PEF 5 min PEF 30 min 
433.7 L/min 227.5 L/min * 310.7 L/min* 344.1 L/min* 
(150-620 
L/min) 
(60-400 L/min) (95-470 L/min) ( 110-480 
L/min) 
* p< 0.0001 
DISCUSSION 
Two long acting beta agonists, salmeterol and formoterol have been released, differing 
substantially in structure, binding to adrenoceptor, B- 2 blockade, onset and mode of 
action(5). 
In stable asthmatics without current symptoms the onset of drug action is less important; 
however, in the acute bronchospastic situation salmeterol lacks an inmediate effect 
while formoterol exibits a similar rapid onset of action to albuterol (1 to 3 minutes), 
achieves maximun bronchodilatation within 2 hours (sustained for up to 12 hours) and 
has almost no adverse side effects(6). It has been shown to be 100 times more potent 
than albuterol "in vitro", without clinically reported tachyphilaxis and controversial 
antiinflamatory properties(6). 
Foradil® is ussually prescribed for inhalation in a dry powder form with a friendly user 
device (Aerolizer®). However, some patients can not perform inhalatory maneuvers for 
a variety of reasons such as age or difficult breathing and the nebulized administration 
of an effective Beta 2 agonist, with both an acute and long lasting effect, might give a 
beneficial therapeutic option in such situations. In this short paper, we have 
demonstrated that asthmatic patients of different ages with acute wheezing 
exacerbations of variable severity have a significant improvement of their PEF using 
formoterol as a dry powder via a nebulized solution. These results suggest the stability 
of this drug in saline solution when it is administered inmediatly after preparation. 
Theoretically, a need for less dosing with an impact on the rate of asthma readmisions, 
because of a prolonged bronchodilatation, might prove cost effective; this will also 
allow patients to initiate and better keep their maintenance medications program. 
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